HealthMore in Health→
Semaglutide analysis links liver-risk subgroup to reduced cardiovascular events
Key Takeaways
- SELECT subgroup analysis focused on patients at elevated fibrosis risk.
- Semaglutide reduced major adverse cardiovascular events across reported fibrosis-risk definitions.
- Fatty liver index fell more with semaglutide than with placebo over 104 weeks.
DE
DT Editorial Team··via nature.com